These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 37848)

  • 21. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased acquisition of a complex appetitive task after MSH and MIF.
    Stratton LO; Kastin AJ
    Pharmacol Biochem Behav; 1975; 3(5):901-4. PubMed ID: 1801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of propranolol on human psychomotor performance.
    Broadhurst AD
    Aviat Space Environ Med; 1980 Feb; 51(2):176-9. PubMed ID: 7362564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression.
    Ehrensing RH; Kastin AJ
    Am J Psychiatry; 1978 May; 135(5):562-6. PubMed ID: 25588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lithium: EEG, performance and mood under subchronic therapy (author's transl)].
    Herrmann WM; Hamann S; Fichte K; Müller-Oerlinghausen B
    Arzneimittelforschung; 1978; 28(9):1520-1. PubMed ID: 582550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease.
    Scholtissen B; Verhey FR; Adam JJ; Prickaerts J; Leentjens AF
    J Neurol Sci; 2006 Oct; 248(1-2):259-65. PubMed ID: 16756999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)].
    Gerstenbrand F; Binder H; Kozma C; Pusch ST; Reisner Th
    Wien Klin Wochenschr; 1975 Dec; 87(24):822-3. PubMed ID: 5815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms.
    Shoemaker RC; House DE
    Neurotoxicol Teratol; 2006; 28(5):573-88. PubMed ID: 17010568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
    Lou JS; Kearns G; Benice T; Oken B; Sexton G; Nutt J
    Mov Disord; 2003 Oct; 18(10):1108-14. PubMed ID: 14534913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial.
    Ondo WG; Silay YS
    Mov Disord; 2006 Oct; 21(10):1614-7. PubMed ID: 16830315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind study to establish the residual effects of zopiclone on performance in healthy volunteers.
    Lader M; Denney SC
    Int Pharmacopsychiatry; 1982; 17 Suppl 2():98-108. PubMed ID: 7188379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Melanostatin (MIF-1): central action and clinical use].
    Puciłowski O; Płaźnik A; Kostowski W
    Pol Tyg Lek; 1983 Jun; 38(24):739-41. PubMed ID: 6139794
    [No Abstract]   [Full Text] [Related]  

  • 35. The influence of a previous thalamotomy on the L-dopa effects on mono-manual dexterity in parkinsonism.
    Knutsson E; Mårtensson A; Meyerson BA; Risberg AM
    Scand J Rehabil Med; 1973; 5(3):130-3. PubMed ID: 4754551
    [No Abstract]   [Full Text] [Related]  

  • 36. Single-dose L-dopa response in early Parkinson's disease: measurements with optoelectronic recording technique.
    Johnels B; Ingvarsson PE; Holmberg B; Matousek M; Steg G
    Mov Disord; 1993; 8(1):56-62. PubMed ID: 8419808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of melanostatin on the central nervous system].
    Chepurnova NE; Borzenkov VM; Chepurnov SA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (2):36-42. PubMed ID: 6132624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychopharmacological and endocrinological effects of melanocyte stimulating hormones in normal man.
    Ashton H; Millman JE; Telford R; Thompson JW; Davies TF; Hall R; Shuster S; Thody AJ; Coy DH; Kastin AJ
    Psychopharmacology (Berl); 1977 Dec; 55(2):165-72. PubMed ID: 23563
    [No Abstract]   [Full Text] [Related]  

  • 39. Pineal vasotocin: release into cat cerebrospinal fluid by melanocyte-stimulating hormone release-inhibiting factor.
    Pavel S; Goldstein R; Gheorghiu C; Calb M
    Science; 1977 Jul; 197(4299):178-9. PubMed ID: 17916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reactivity of patients under lithium-therapy/assessment of multivariate relationships (author's transl)].
    Opgenoorth E; Lenz G; Sperlich S; Wytek R
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Jul; 13(4):182-99. PubMed ID: 7443774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.